Moleculin Biotech, Inc.
Price Action
Technical Summary
WEAKENINGMoleculin Biotech, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings growth of 100% provides fundamental context to the price action. Investors should exercise caution due to high volatility (121% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.77 | -16.20% | BELOW |
| 50 SMA | $2.58 | -10.06% | BELOW |
| 100 SMA | $2.56 | -9.33% | BELOW |
| 150 SMA | $3.26 | -28.77% | BELOW |
| 200 SMA | $5.34 | -56.52% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MBRX in an uptrend right now?
MBRX has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is MBRX overbought or oversold?
MBRX's RSI (14) is 43. The stock is in neutral territory, neither overbought nor oversold.
Is MBRX outperforming the market?
MBRX has a Relative Strength (RS) Rating of 96 out of 99. Yes, MBRX is a market leader, outperforming 96% of all stocks over the past 12 months.
Where is MBRX in its 52-week range?
MBRX is trading at $2.32, which is 29% of its 52-week high ($7.98) and 27% above its 52-week low ($0.26).
How volatile is MBRX?
MBRX has a Beta of 0.89 and 52-week volatility of 121%. It's less volatile than the S&P 500 - generally more stable.